Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

State Street SPDR S&P Biotech ETF (NY:XBI)

146.95 -0.06 (-0.04%)

Streaming Delayed Price Updated: 3:09 PM EDT, Aug 3, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	5,342,214
Open	146.98
Bid (Size)	146.91 (300)
Ask (Size)	146.95 (200)
Prev. Close	147.01
Today's Range	143.78 - 148.15
52wk Range	84.52 - 165.71
Shares Outstanding	541,500
Dividend Yield	0.19%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Which Is the Better State Street Healthcare ETF: The Broad XLV or the Biotech XBI? ↗

Today 7:45 EDT

XBI surged 76% in one year but carries triple the expense ratio and far steeper downside risk. Which fund matches your risk appetite?

Via The Motley Fool

Here's How Much $100 Invested In State Street SPDR S&P Biotech ETF 20 Years Ago Would Be Worth Today ↗

July 13, 2026

State Street SPDR S&P Biotech ETF (NYSE:XBI) has outperformed the market over the past 20 years by 3.16% on an annualized basis producing an average annual return of 12.55%. Currently, State Street...

Via Benzinga

Performance

YTD	+20.9%	+20.9%
1 Month	-8.6%	-8.6%
3 Month	+10.1%	+10.1%
6 Month	+15.4%	+15.4%
1 Year	+69.3%	+69.3%

More News

Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026? ↗

July 09, 2026

Via The Motley Fool

Fidelity Health Care vs. State Street Biotech: Which ETF Fits Your Portfolio Best? ↗

July 05, 2026

Via The Motley Fool

The Best Biotech Stocks to Buy in 2026 ↗

June 17, 2026

Via The Motley Fool

Is iShares Pharma ETF (IHE) or SPDR's Biotech ETF (XBI) the Better Long-Term Buy for Investors? ↗

June 17, 2026

Via The Motley Fool

3 Longevity ETFs to Buy and Hold (and Hold) ↗

June 08, 2026

Via MarketBeat

Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech ↗

June 05, 2026

Via The Motley Fool

VHT vs. XBI: Vanguard Health Care ETF Tops SPDR Biotech in Yield and Cost ↗

May 28, 2026

Via The Motley Fool

2 Ways to Play the Big Pharma Patent Cliff ↗

May 15, 2026

Via MarketBeat

Small Caps Under Siege: Russell 2000 Enters Correction as Yields Surge

March 23, 2026

Via MarketMinute

DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing ↗

March 21, 2026

Via The Motley Fool

IBRX Stock Rises Overnight: Retail Bets Anktiva’s NCCN 'Recommended' Tag Will Drive Prescriptions And Insurance Wins ↗

March 17, 2026

Via Stocktwits

The Azetukalner Breakthrough: A Deep Dive into Xenon Pharmaceuticals (XENE)

March 12, 2026

Via Finterra

Battered Polaryx Stock Turns Retail-Trader Heads After 70% Surge: What’s Behind The Sudden Interest? ↗

March 11, 2026

Via Stocktwits

QURE Stock Edges Up After Hours As Analyst Flags Reduced Regulatory Uncertainty Following Prasad’s FDA Exit ↗

March 10, 2026

Via Stocktwits

QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure ↗

March 10, 2026

Via Stocktwits

QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 ↗

March 09, 2026

Via Stocktwits

IBRX Stock Declines Pre-Market — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data ↗

March 09, 2026

Via Stocktwits

ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns ↗

March 05, 2026

Via Stocktwits

Why Did CRMD Stock Tumble Over 11% Today? ↗

March 05, 2026

Via Stocktwits

Why Did BTAI Stock Surge 20% In Pre-Market Today? ↗

March 05, 2026

Via Stocktwits

Liquidia Stock Gains Premarket On Q4 Revenue Beat – Investors Are Betting On YUTREPIA Growth ↗

March 05, 2026

Via Stocktwits

DAWN Shares Rally On Buyout Speculation But Retail Warns A Deal Might Not Materialise ↗

March 04, 2026

Via Stocktwits

IBRX Stock Drops On Investor Concerns Over Immunotherapy Launch In Saudi Arabia Amid Middle East Tensions But Analyst Sees 20% Upside ↗

March 04, 2026

Via Stocktwits

Frequently Asked Questions

Is State Street SPDR S&P Biotech ETF publicly traded?

Yes, State Street SPDR S&P Biotech ETF is publicly traded.

What exchange does State Street SPDR S&P Biotech ETF trade on?

State Street SPDR S&P Biotech ETF trades on the New York Stock Exchange

What is the ticker symbol for State Street SPDR S&P Biotech ETF?

The ticker symbol for State Street SPDR S&P Biotech ETF is XBI on the New York Stock Exchange

What is the current price of State Street SPDR S&P Biotech ETF?

The current price of State Street SPDR S&P Biotech ETF is 146.95

When was State Street SPDR S&P Biotech ETF last traded?

The last trade of State Street SPDR S&P Biotech ETF was at 08/03/26 03:09 PM ET

What is the market capitalization of State Street SPDR S&P Biotech ETF?

The market capitalization of State Street SPDR S&P Biotech ETF is 79.57M

How many shares of State Street SPDR S&P Biotech ETF are outstanding?

State Street SPDR S&P Biotech ETF has 80M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.